Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Immunmodulering under Palynziq®-behandling hos voksne (IMPALA)

6. november 2026 oppdatert av: BioMarin Pharmaceutical

En fase 4-studie av immunmodulering under Palynziq®-behandling hos voksne med fenylketonuri (PKU)

Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

The overall objective of the study is to evaluate the ability of MTX, when co-administered with Palynziq, to suppress immune responses to Palynziq and thus improve the tolerability and efficacy of Palynziq in adults with phenylketonuria (PKU). Up to 12 participants will be enrolled into the study across 2 cohorts, with a target enrollment of 6 participants into each cohort:

  • Cohort A: Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq (Palynziq naïve)
  • Cohort B: Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of≥ 20mg/day, and are unable to further dose escalate (Palynziq experienced)

Palynziq will be initiated (Cohort A) or will continue (Cohort B) as indicated in the Palynziq United States Prescribing Information (USPI) and as prescribed by the participant's treating physician. The decision to initiate or continue Palynziq must be made independently of participation in this study. Palynziq and MTX will not be supplied by BioMarin as part of participation in this study.

All participants will be administered MTX at an oral dose of 15 mg/week concurrent with Palynziq:

  • Cohort A participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently.
  • Cohort B participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq.

After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49; Follow-up Period).

Participants will be assessed for safety and MTX tolerability. If a participant in either Cohort A or B is unable to tolerate MTX, the participant will be discontinued from MTX treatment. Participants who discontinue from MTX early should continue to complete the remaining study assessments until as long as such continued participation will not detrimentally affect the health, safety, and welfare of the participant per investigator determination

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • UCLA Dept. of Human Genetics
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado
    • Florida
      • Tampa, Florida, Forente stater, 33613
        • Rekruttering
        • University Of South Florida Medical Center
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University School of Medicine
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota Medical School
    • New York
      • Rochester, New York, Forente stater, 14642
        • Rekruttering
        • University of Rochester Medical Center (URMC)
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Rekruttering
        • Oregon Health & Science University (OHSU) - PARENT
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Har ikke rekruttert ennå
        • University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • Rekruttering
        • UT Southwestern Medical Center
        • Ta kontakt med:
          • Markey McNutt
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • Har ikke rekruttert ennå
        • University of Utah Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Children's Hospital of Wisconsin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults between 18 and 65 years old
  • Have a confirmed diagnosis of phenylketonuria (PKU)
  • Are in generally good health based on medical evaluation
  • Are willing and medically eligible to receive Palynziq and methotrexate (MTX) Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood > 600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20mg and unable to increase the dose further
  • Agree to use required contraception if they or their partner could become pregnant
  • Are willing to carry two epinephrine devices at all times during Palynziq treatment

Exclusion Criteria:

  • Pregnant, breastfeeding, planning to become pregnant, planning to father a child, or not using effective birth control if applicable
  • Have a known severe allergy or hypersensitivity reaction to methotrexate (MTX), Palynziq, or other PEG-containing medications
  • Have a serious active infection or a history of severe or recurrent infections
  • Have significant medical conditions that may affect safety or participation (such as serious heart, lung, liver, kidney, immune, neurological, psychiatric, or cancer-related conditions)
  • Have a history of substance or alcohol abuse within the past 12 months
  • Have had an organ transplant or are taking chronic immunosuppressive medications
  • Are currently taking medications that are not allowed in the study, including other PKU treatments besides Palynziq
  • Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study
  • Have major surgery planned during the study participation period
  • Are currently participating in another clinical study involving Palynziq
  • In the opinion of the study doctor, are not a suitable candidate for the study or may have difficulty complying with study requirements

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Palynziq naïve

Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq. Participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49).

Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.

Andre navn:
  • Palynziq

Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.

Andre navn:
  • MTX
Eksperimentell: Palynziq experienced

Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of ≥ 20mg/day and are unable to further dose escalate (Palynziq experienced). Participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49).

Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.

Andre navn:
  • Palynziq

Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.

Andre navn:
  • MTX

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in blood Phe levels from baseline to Week 25 and Week 49
Tidsramme: Baseline to Week 25 and Baseline to Week 49

To evaluate blood Phe response in adults with PKU co-administered Palynziq with MTX for 6 months

Baseline to Week 25 and Baseline to Week 49
Anti-PEG IgG, IgM, anti-PAL IgG, IgM levels at Weeks 5, 9, 25, and 49
Tidsramme: Baseline to Week 5, Week 9, Week 25, and Week 49

To evaluate the ability of MTX to modulate the immune response to Palynziq in adults with PKU

Baseline to Week 5, Week 9, Week 25, and Week 49

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of TEAEs
Tidsramme: Baseline through Week 49

To evaluate the safety of co-administration of Palynziq with MTX in adults with PKU. A TEAE is defined as any AE that newly appeared, increased in frequency, or worsened in severity following initiation of the study drugs (MTX or Palynziq) administration. Incidence of TEAEs will be defined as (number of TEAEs)/(total exposure time in person-years) *100

Baseline through Week 49
Trough Palynziq plasma PK
Tidsramme: Baseline through Week 49

To characterize the PK of Palynziq during co-administration with MTX in adults with PKU

Baseline through Week 49

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in IgG-C3d CIC, C3, C4 levels from baseline to Weeks 9, 25, and 49
Tidsramme: Baseline to Weeks 9, 25, and 49

To evaluate formation of CIC and activation of complement pathway. Change from baseline to time t for each participant will be defined as (blood level at time t) - (blood level at baseline)

Baseline to Weeks 9, 25, and 49
Percentage of participants in Cohort B that have escalated from dose at enrollment
Tidsramme: Baseline to Week 24 and Week 48

To evaluate ability to dose escalate in Cohort B participants following co-administration of Palynziq with MTX

Baseline to Week 24 and Week 48

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Medical Director, MD, BioMarin Pharmaceutical

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mai 2026

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

30. september 2027

Datoer for studieregistrering

Først innsendt

13. mars 2026

Først innsendt som oppfylte QC-kriteriene

13. mars 2026

Først lagt ut (Faktiske)

17. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere